Konstantinos Xynos Sells 7,246 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Replimune Group Trading Up 35.1 %

REPL opened at $14.93 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The firm’s fifty day moving average is $11.51 and its 200 day moving average is $9.67. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07. Research analysts forecast that Replimune Group, Inc. will post -3.02 EPS for the current fiscal year.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC boosted its position in shares of Replimune Group by 165.5% during the third quarter. Barclays PLC now owns 158,491 shares of the company’s stock worth $1,738,000 after acquiring an additional 98,791 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Replimune Group by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after purchasing an additional 217,308 shares during the last quarter. State Street Corp grew its position in shares of Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after purchasing an additional 1,182,181 shares in the last quarter. Parkman Healthcare Partners LLC increased its holdings in shares of Replimune Group by 45.5% in the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock worth $8,371,000 after purchasing an additional 238,747 shares during the last quarter. Finally, Arizona PSPRS Trust purchased a new stake in shares of Replimune Group in the third quarter worth about $834,000. Institutional investors own 92.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Roth Mkm began coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. HC Wainwright reiterated a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a research report on Friday. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Finally, BMO Capital Markets raised their target price on Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $17.00.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.